29th & 30th March 2017

Chairpersons

Dr Sergio Quezada
Head of the Immune Regulation
and Tumour Immunotherapy Group
UCL Cancer Institute
London, UK
Dr Padmanee Sharma
Scientific Director, Immunotherapy Platform;
Professor, Department of Genitourinary Medical Oncology;
Professor, Department of Immunology;
Co-Director, Parker Institute for Cancer Immunotherapy,
MD Anderson Cancer Center, Houston, TX, USA

Please click here for a printable PDF version of this programme.

Please note that timings are provisional and subject to change.
Speaker Conflict of Interest forms are here
Confirmation of accreditation is here
Wednesday Morning

Scientific Session 1

08.00
Badge Collection and Coffee

09:00
Eradicating tumors using the immune system
Professor Robert Schreiber, PhD
Alumni Professor, Pathology and Immunology, Director, Center for Human Immunology and Immunotherapy Programs, Washington University, St. Louis, MO. USA


09.30
Immune checkpoint in cancer therapy:  New insights into mechanism
Dr James P. Allison
Department Chair, Department of Immunology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA


10.00
From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy
Dr Padmanee Sharma
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA


10.30
Panel Q&A


10:45
Coffee Break


11:15
Industry Symposium 1 (45 mins)


12:00
The affordability of the extraordinary
Professor Richard Sullivan
Director of the Institute of Cancer Policy and King’s Health Partners Integrated Cancer Centre Global Health Work, London, UK


12:45
Lunch


Wednesday Afternoon

13:45
Industry Symposium 2 (45 mins)


Scientific Session 2

14:30
Targeting the cancer mutanome
Dr Alena Gros Vidal
Group Leader, Vall d’Hebron Institute of Oncology, Barcelona, Spain


15:00
Coffee Break


15.30
Radiation treatment and immunotherapy combinations to improve outcome for cancer patients
Professor Tim Illidge
Professor of Targeted Therapy and Oncology, Institute of Cancer Sciences, Faculty of Medical & Human Sciences, University of Manchester, Manchester, UK


16.00
Molecular and epigenetic programs defining tumor-specific T cell dysfunction
Dr Andrea Schietinger
Principal Investigator, Assistant Member, Memorial Sloan Kettering Cancer Center, New York, NY, USA


16.30
The tumor microenvironment and the dynamics of the immune response in human tumors
Dr Jerome Galon
Research Director, Integrative Cancer Immunology Laboratory, INSERM, Paris, France


17.00
Panel Q&A

17:15
Close


Thursday Morning
08.00
Badge Collection and Coffee

Scientific Session 3 with The Lancet Oncology

08:30
Trends & Collaborations in the IO Space
Dr Ramy Ibrahim
VP and Head of R&D, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA

09.00
Deciphering immune regulation and recognition at the tumour site
Dr Sergio Quezada
Head of the Immune Regulation and Tumour Immunotherapy group, UCL Cancer Institute, London, UK

09.30
Immune biomarkers and measuring response
Professor Alexander MM Eggermont
Director General of Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

10.00
Immuno-oncolytic viruses as cancer therapies
Professor Alan Melcher
Professor of Translational Immunotherapy; Team Leader, Translational Immunotherapy Team, The Institute of Cancer Research, London, UK

10.30
Panel Q&A


10:45
Coffee Break


11:15
Industry Symposium 3 (45 mins)


Thursday Afternoon

Scientific Session 4

12:00
Immune-based therapies for childhood cancer
Professor Crystal Mackall
Professor, Pediatrics & Medicine; Associate Director, Stanford Cancer Institute, Stanford Medical School, Stanford, CA, USA


12:30
Lunch


13.30
Emerging approaches in melanoma immunotherapy
Dr Christian Blank
Group Leader at the Division of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

14.00
The interplay between panomics and immunotherapy to advance therapy
Professor Charles Swanton
Cancer Research UK Senior Clinical Research Fellow & Group Leader of the Translational Cancer Therapeutics Laboratory, UCL Cancer Institute and Francis Crick Institute, UK


14:30
Coffee Break


15:00
New insights on the mechanisms regulating the synergy of radiotherapy with immune checkpoint inhibitors
Professor Sandra Demaria
Professor of Radiation Oncology and Pathology, Weill Cornell Medical College, New York, NY, USA

15.30
Erika Pearce
Metabolic competition in the tumor microenvironment is a driver of cancer progression
Dr Erika Pearce
Director of the Institute; Head of the department of Immunometabolism, the Max Planck Institute of Immunobiology and Epigenetics, Freiberg, Germany


16.00
Panel Q&A


Keynote Presentation

16.10
Ongoing development of checkpoint trials
Dr James Larkin
Consultant Medical Oncologist, The Royal Marsden Hospital, London, UK

16:55
Close

ACI is supported by sponsorship from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.